Thrivent Financial for Lutherans’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Thrivent Financial for Lutherans’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-262,358	Closed	-$341K	–	2057
2018 Q3	$341K	Hold	262,358	–	–	﹤0.01%	1833
2018 Q2	$354K	Hold	262,358	–	–	﹤0.01%	1839
2018 Q1	$380K	Sell	262,358 -35,945	-12%	-$75.1K	﹤0.01%	1772
2017 Q4	$671K	Buy	298,303 +55	+0%	+$139	﹤0.01%	1490
2017 Q3	$1.01M	Hold	298,248	–	–	﹤0.01%	1151
2017 Q2	$1.06M	Sell	298,248 -115,030	-28%	-$379K	﹤0.01%	1094
2017 Q1	$1.41M	Hold	413,278	–	–	0.01%	993
2016 Q4	$1.9M	Hold	413,278	–	–	0.01%	876
2016 Q3	$1.75M	Hold	413,278	–	–	0.01%	917
2016 Q2	$992K	Hold	413,278	–	–	﹤0.01%	1099
2016 Q1	$1.94M	Buy	413,278 +147,930	+56%	+$572K	0.01%	871
2015 Q4	$1.04M	Buy	+265,348	New	+$1.22M	0.01%	1051

Other funds holding AST

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Thrivent Financial for Lutherans's AST Position: Q4 2018 in Review

Thrivent Financial for Lutherans sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 262,358 shares — an estimated $341K sold.

Thrivent Financial for Lutherans first reported a position in AST in Q4 2015 and held it in 12 quarters. The position peaked at $1.94M in Q1 2016. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

Thrivent Financial for Lutherans reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
Thrivent Financial for Lutherans sold 262,358 Asterias Biotherapeutics Inc. Series A shares in Q4 2018, an estimated $341K.
Thrivent Financial for Lutherans first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2015 and held it in 12 quarters.
Thrivent Financial for Lutherans's Asterias Biotherapeutics Inc. Series A position peaked at $1.94M in Q1 2016.
46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2018, filed 15 Feb 2019.